VisitorsCoverage Launches Treppy MCP Server to Power AI-Driven Travel Insurance
Key Features of the Treppy MCP Server
- Full Quote-to-Compare Flow: Access real-time quotes from multiple carriers directly within AI workflows
- Accurate Plan Information: Up-to-date coverage and eligibility details for hundreds of plans
- Ready-to-Scale: Supports any MCP-capable AI agent — including OpenAI, Claude, Cursor, Cline, and custom agent stacks
What Is the Market Impact?
With the global travel insurance market projected to surpass
The travel insurance MCP server is free to use during the public beta and available immediately at treppy.io/mcp-server-for-travel-insurance.
"AI agents are becoming a primary channel for travel research and booking, yet insurance remains bogged down by bespoke integrations," said
About Treppy®
Treppy®, powered by VisitorsCoverage®, is a leading SaaS solution designed to simplify travel insurance distribution. Since its 2022 relaunch, Treppy has enabled agencies to launch digital storefronts with zero technical expertise. As of 2026, Treppy's MCP server further evolves the platform and enables developers to build AI agents capable of delivering unified-carrier coverage in real-time, making travel protection more accessible than ever.
About VisitorsCoverage Inc.
Founded in 2006, VisitorsCoverage has helped millions of customers in over 175 countries find the travel insurance they need to feel safe, secure, and well prepared for their journeys. Our award-winning and innovative marketplace of top-rated travel medical and trip insurance plans helps travelers research, compare, and buy affordable visitors and travel insurance online in minutes. Find insurance for the way you travel at VisitorsCoverage.com.
View original content to download multimedia:https://www.prnewswire.com/news-releases/visitorscoverage-launches-treppy-mcp-server-to-power-ai-driven-travel-insurance-302794683.html
SOURCE VisitorsCoverage Inc.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Lilly's Jaypirca (pirtobrutinib) significantly reduced the risk of disease progression or death by 45% when added to a venetoclax time-limited regimen in people with previously treated CLL/SLL
- Legend Biotech Establishes Clinical Proof-of-Concept for LB2501, a Potential First-in-Class In Vivo CD19/CD20 Dual-Targeting CAR-T, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma
- OM Pharma to Unveil the Largest Multi-Country Real-World Evidence Study on Broncho‑Vaxom® (OM‑85) for RTI Prevention at EAACI 2026
Create E-mail Alert Related Categories
PRNewswire, Press ReleasesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share